/PRNewswire/ Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for.
/PRNewswire/ Shore Bancshares, Inc. (NASDAQ - SHBI) (the "Company") reported net income of $4.617 million or $0.39 per diluted common share for the third.
/PRNewswire/ Shore Bancshares, Inc. (NASDAQ - SHBI) (the "Company") reported net income of $4.617 million or $0.39 per diluted common share for the third.